Product Description
M6P Therapeutics is developing M-052 as a treatment for Fabry disease. (Sourced from: https://m6ptherapeustg.wpengine.com/our-focus/pipeline/)
Mechanisms of Action: Gene Therapy,GLA
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: M6P Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Fabry Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|